Lysosomal Alpha-D-Mannosidase Deficiency

Alpha-mannosidosis is a rare, inherited disease. A child is born with it when both parents pass down a changed copy of a gene called MAN2B1. This gene makes an enzyme named alpha-D-mannosidase. The enzyme’s job is to break down certain sugar-rich molecules (glycoproteins) inside small cell bags called lysosomes. When the enzyme is missing or weak, those partly-broken sugars build up inside cells all over the body. Over time, this buildup harms many organs and systems, including the brain, immune system, ears, bones, joints, lungs, and sometimes the eyes. Symptoms often include frequent infections, hearing loss, balance or walking problems, learning problems, behavior changes, coarse facial features, and bone/joint issues. The illness can be mild or severe. It usually gets worse without treatment, but early care can slow or improve many problems. NCBI+2BioMed Central+2

Alpha-mannosidosis is a rare, inherited disease of the lysosome—the “recycling center” inside our cells. In healthy cells, an enzyme called alpha-D-mannosidase cuts sugar chains (rich in the sugar mannose) into smaller pieces so the cell can reuse them. In alpha-mannosidosis, this enzyme is missing or works very poorly because of changes (variants) in a gene called MAN2B1. As a result, mannose-rich oligosaccharides build up inside many tissues. Over time, this storage causes learning and thinking problems, hearing loss, frequent infections, problems with balance and movement, and changes in bones and joints. The condition is autosomal recessive, which means a child is affected when both copies of the MAN2B1 gene carry harmful variants. MedlinePlus+3NCBI+3Orpha+3

---

Other names

People use several names for the same condition:

• Alpha-mannosidosis

• Lysosomal alpha-D-mannosidase deficiency

• MAN2B1 deficiency

• Acid alpha-mannosidase deficiency

• Lysosomal storage disease due to alpha-mannosidase deficiency

All of these refer to the same disorder caused by biallelic pathogenic variants in MAN2B1. NCBI+1

---

Types

Doctors now think of alpha-mannosidosis as a spectrum. Symptoms can be mild, moderate, or severe and often worsen slowly over time. In the past, some papers split cases into “type I (severe)” and “type II (mild/adult),” but this split is not very reliable because many people fall in-between. Today, the focus is more on the person’s actual symptoms and rate of progression rather than on strict type labels. MedLink+1

---

Causes

There is one root cause: too little working alpha-D-mannosidase because of disease-causing variants in MAN2B1. Below are 20 clear ways or situations that lead to that same root problem. These are worded simply; many are standard genetic mechanisms seen in lysosomal diseases.

1. Biallelic pathogenic variants in MAN2B1 (both copies changed) → low or no enzyme activity. NCBI

2. Missense variants that change one amino acid and reduce enzyme function or stability. NCBI

3. Nonsense variants that introduce a “stop” signal and truncate the enzyme early. NCBI

4. Frameshift variants (small insertions/deletions) that disrupt the reading frame and produce nonfunctional protein. NCBI

5. Splice-site variants that lead to mis-spliced RNA and faulty protein. NCBI

6. Large deletions or duplications (copy-number variants) that remove or duplicate parts of MAN2B1. PreventionGenetics

7. Compound heterozygosity—two different harmful variants, one on each gene copy. NCBI

8. Homozygosity due to parental relatedness (consanguinity), increasing the chance of inheriting the same harmful variant from both parents. PubMed

9. Founder variants in certain populations where a specific MAN2B1 change is more common. BioMed Central

10. Variants that impair proper folding of the enzyme, so it is destroyed by the cell’s quality-control (ER-associated degradation). BioMed Central

11. Variants that disrupt lysosomal targeting signals, so the enzyme does not reach the lysosome in sufficient amounts. BioMed Central

12. Changes at catalytic residues that directly reduce the enzyme’s cutting activity. BioMed Central

13. Variants that remove glycosylation sites, making the enzyme unstable. BioMed Central

14. Promoter or regulatory variants that lower MAN2B1 expression. BioMed Central

15. Complex alleles (two nearby changes on the same gene copy) that together damage function. BioMed Central

16. Dominant-negative–like effects are not the cause; this disease is recessive—two damaged copies are needed. (Stated to avoid confusion.) NCBI

17. Residual-activity variants that leave some enzyme function; these usually lead to milder, later-onset disease. NCBI

18. Mosaicism in a parent can rarely explain unexpected inheritance patterns, though the child still needs two pathogenic alleles. NCBI

19. Uniparental isodisomy (rare) could cause two copies of a single harmful allele to be inherited from one parent. (General mechanism described in genetics references; included for completeness.) NCBI

20. No environmental cause—exposures do not cause alpha-mannosidosis; they only influence health once the genetic condition is present. NCBI

---

Symptoms

Symptoms vary widely. Many start in early childhood and progress slowly. Not everyone has all features.

1. Learning and intellectual disability—mild to moderate, often with speech delay. NCBI+1

2. Hearing loss, often conductive at first and sometimes mixed or sensorineural later. Orpha+1

3. Frequent infections (ear, sinus, chest) due to immune problems. Orpha+1

4. Problems with balance and coordination (ataxia); clumsiness or unsteady walk. NCBI

5. Coarse facial features (broad forehead, large head, widely spaced teeth, large tongue) that become more obvious with age. MedlinePlus

6. Skeletal changes (dysostosis multiplex)—curved spine, chest or hip shape changes, joint laxity or contractures. NCBI

7. Enlarged liver and/or spleen (hepatosplenomegaly). National Organization for Rare Disorders

8. Developmental delay (motor and language). NCBI

9. Behavioral or emotional challenges (attention, anxiety, frustration due to hearing/speech limits). NCBI

10. Fatigue and reduced stamina, especially during or after infections. National Organization for Rare Disorders

11. Headaches or increased pressure in the head in some, including rare hydrocephalus. BioMed Central

12. Muscle weakness and fine-motor difficulty (buttoning, writing). NCBI

13. Speech and language impairment, often linked to hearing loss and oral anatomy. NCBI

14. Vision issues may occur (strabismus, refractive errors), though severe eye clouding is less typical than in some other lysosomal disorders. NCBI

15. Slow, stepwise progression—symptoms often intensify with age without treatment. BioMed Central

---

How doctors diagnose it

Big picture: Diagnosis starts with clinical suspicion based on symptoms. Doctors then look for mannose-rich oligosaccharides in body fluids and measure the enzyme’s activity. A genetic test of MAN2B1 confirms the exact variants. Other studies help define hearing, bones, brain, and immunity so care can be tailored. NCBI

A) Physical examination

1. General growth and facial exam – The clinician looks for coarse facial features (broad forehead, large tongue, widely spaced teeth) and checks head size. These external signs can point toward a lysosomal disorder like alpha-mannosidosis. MedlinePlus

2. Musculoskeletal exam – The doctor inspects the spine, chest, hips, and joints for curvature, stiffness, or laxity that suggest dysostosis multiplex. Findings guide imaging and rehabilitation. NCBI

3. Neurologic exam – Balance, gait, reflexes, and coordination are tested to look for ataxia and fine-motor problems. This helps decide if brain imaging or therapy is needed. NCBI

4. ENT and hearing-related exam – The ears, nose, and throat are checked for chronic infections or fluid that might worsen hearing. Physical signs, together with hearing tests, support the diagnosis. Orpha

5. Abdominal exam – The liver and spleen are felt for enlargement (hepatosplenomegaly), a common clue to a storage disease. National Organization for Rare Disorders

B) “Manual” bedside tests (simple, hands-on checks)

6. Tuning-fork hearing tests (Rinne and Weber) – Quick checks that help tell conductive from sensorineural hearing loss at the bedside before formal audiology. They guide the next tests. (Standard ENT practice applied to this disease context.)

7. Romberg test – Standing with feet together and eyes closed to check balance; swaying suggests sensory or cerebellar issues seen in ataxia.

8. Tandem gait – Heel-to-toe walking to screen coordination and equilibrium, often abnormal when alpha-mannosidosis affects balance.

9. Manual muscle testing – Grading limb strength to document weakness and track change over time with therapy or treatment.

These bedside maneuvers don’t prove the disease, but they support suspicion and help plan deeper testing.

C) Laboratory and pathological tests (core for confirmation)

10. Urine oligosaccharide screen – Looks for mannose-rich oligosaccharides that accumulate in alpha-mannosidosis. A positive screen raises suspicion but is not definitive. PMC+1

11. Serum/plasma oligosaccharide analysis – Measures specific free oligosaccharides in blood; helps support the diagnosis and monitor trends. GGC

12. Alpha-mannosidase enzyme assay (leukocytes or fibroblasts) – The key biochemical test. Markedly low enzyme activity confirms the diagnosis when clinical signs fit. Neurology Catalog+1

13. MAN2B1 genetic testing – Sequencing (and copy-number analysis) identifies the exact variants. This confirms the cause, informs family testing, and may predict severity based on residual activity. PreventionGenetics

14. Immune work-up – Complete blood count and immunoglobulin levels (IgG/IgA/IgM) to look for immunodeficiency that explains frequent infections and guides preventive care. Orpha

15. Newborn or high-risk family testing (targeted) – In families with known variants, labs can test a new baby early by enzyme activity and/or targeted genetic testing to enable early care. NCBI

D) Electrodiagnostic tests (electrical studies that add detail)

16. Audiology with auditory brainstem response (ABR/BAEP) – Objective test of hearing pathways; helpful when young children cannot complete standard hearing tests. Results guide hearing aids or other support. Alpha Mannosidosis

17. EEG (electroencephalogram) – Used if seizures or staring spells are suspected; some patients with lysosomal diseases can develop seizures. (General neurologic approach in progressive disorders.) NCBI

18. Nerve conduction studies/EMG (as needed) – If there is unexplained weakness or numbness, these tests assess nerve and muscle function to separate peripheral from central causes. (Applied clinical practice.)

E) Imaging tests (pictures that show internal changes)

19. Skeletal survey (X-rays) – Looks for dysostosis multiplex: spine curvature, chest/hip changes, or other bone signs that support a lysosomal storage disorder. NCBI

20. Brain MRI – May show white-matter changes, cerebellar or other structural issues that match the person’s balance and learning problems. Imaging also helps evaluate hydrocephalus if symptoms point to it. BioMed Central

Non-pharmacological treatments (therapies and others)

1. Genetic counseling for the family
   Purpose: explain inheritance, testing for relatives, and future pregnancy options.
   Mechanism: education and risk calculation based on the MAN2B1 gene. NCBI

2. Early intervention and special education
   Purpose: support learning, speech, and behavior from toddler age.
   Mechanism: structured teaching, communication strategies, and adaptive tools matched to cognitive profile. NCBI

3. Physiotherapy (physical therapy)
   Purpose: improve posture, balance, strength, and endurance; reduce contractures.
   Mechanism: task-specific exercise, stretching, gait training, and orthoses.

4. Occupational therapy
   Purpose: make daily living (dressing, writing, feeding) easier.
   Mechanism: fine-motor training, joint protection, assistive devices, and home/workplace adaptations.

5. Speech and language therapy
   Purpose: improve speech clarity and language; support swallowing if needed.
   Mechanism: articulation training, language exercises, and swallowing techniques.

6. Audiology care with hearing aids or implants
   Purpose: treat conductive or sensorineural hearing loss, common in this condition.
   Mechanism: amplification devices; bone-anchored aids or cochlear implants in selected cases. BioMed Central

7. ENT care for recurrent ear/sinus infections
   Purpose: reduce infections and improve hearing.
   Mechanism: ventilation (grommet) tubes, adenoid/tonsil evaluation, airway management. BioMed Central

8. Breathing and sleep care
   Purpose: manage snoring or sleep apnea, reduce daytime fatigue.
   Mechanism: sleep study; positional therapy; CPAP if indicated.

9. Orthopedic management
   Purpose: address foot deformities, scoliosis, hip or knee problems, and pain.
   Mechanism: bracing, custom footwear, physiotherapy; surgery when needed. BioMed Central

10. Pain management without medicines when possible
    Purpose: reduce joint/muscle pain safely.
    Mechanism: heat/cold therapy, stretching, pacing, TENS, posture training.

11. Infection prevention practices
    Purpose: lower respiratory and ear infections.
    Mechanism: vaccinations on time, hand hygiene, prompt dental/ENT care. BioMed Central

12. Nutrition counseling
    Purpose: maintain healthy weight, bone health, and energy.
    Mechanism: balanced calories, adequate protein, calcium, vitamin D; texture adjustments for swallowing.

13. Psychological and behavioral support
    Purpose: manage anxiety, frustration, and behavior changes; support caregivers.
    Mechanism: cognitive-behavioral strategies, routines, and respite care.

14. Vision care
    Purpose: detect and correct cataract/strabismus or other issues.
    Mechanism: glasses, patching, or surgery if needed. BioMed Central

15. Dental/orthodontic care
    Purpose: prevent decay, manage crowding/malocclusion common in lysosomal disorders.
    Mechanism: fluoride, sealants, early orthodontic review. BioMed Central

16. Vaccination optimization
    Purpose: reduce infections given immune vulnerability.
    Mechanism: follow national schedules; consider extra counseling before/after HSCT/ERT. BioMed Central

17. Social work and disability services
    Purpose: access benefits, mobility aids, school supports.
    Mechanism: practical planning, equipment grants, transportation help.

18. HSCT patient selection and prep (non-drug aspects)
    Purpose: for selected children with severe disease to preserve neurodevelopment.
    Mechanism: donor search, transplant center evaluation, and timing before major decline. ScienceDirect

19. Respiratory physiotherapy
    Purpose: help clear mucus and reduce chest infections.
    Mechanism: airway clearance techniques, incentive devices.

20. Care coordination in a rare-disease center
    Purpose: align genetics, neurology, ENT, ortho, rehab, and metabolic care in one plan.
    Mechanism: multidisciplinary clinics and shared care pathways. Genetic and Rare Diseases Center

---

Drug treatments

Important: exact dosing must be individualized by the treating specialist. Below are typical, label-based, or common clinical uses for alpha-mannosidosis and its complications.

1. Velmanase alfa (Lamzede®) — Enzyme replacement therapy
   Class: recombinant human alpha-mannosidase.
   Dose/Time: 1 mg/kg IV infusion once weekly (pediatric and adult). Consider pre-medication (antihistamine/antipyretic ± corticosteroid) to reduce infusion reactions.
   Purpose: treat non-CNS manifestations; lower serum oligosaccharides; improve functional capacity and infection burden in many patients.
   Mechanism: replaces the missing enzyme so cells can clear stored sugars.
   Side effects: infusion reactions, fever, chills, headache, joint pain, rash; rare anaphylaxis; anti-drug antibodies possible. Lamzede+3FDA Access Data+3Lamzede+3

2. Acetaminophen (paracetamol)
   Class: analgesic/antipyretic.
   Dose/Time: per weight; commonly 10–15 mg/kg every 4–6 h (max per local guidelines).
   Purpose: pain/fever control, including around infusions.
   Mechanism: central COX modulation.
   Side effects: liver toxicity if overdosed.

3. Ibuprofen
   Class: NSAID.
   Dose/Time: weight-based every 6–8 h with food.
   Purpose: musculoskeletal pain/inflammation.
   Mechanism: COX inhibition.
   Side effects: stomach upset, ulcers, kidney effects; avoid near HSCT conditioning as directed.

4. Amoxicillin (or amoxicillin-clavulanate)
   Class: beta-lactam antibiotic.
   Dose/Time: standard ENT/respiratory dosing for acute otitis media/sinusitis.
   Purpose: treat common ENT infections.
   Mechanism: inhibits bacterial cell wall.
   Side effects: rash, diarrhea; allergy risk.

5. Azithromycin
   Class: macrolide antibiotic.
   Dose/Time: standard 3–5 day courses when indicated or if penicillin-allergic.
   Purpose: treat bacterial respiratory infections.
   Mechanism: blocks bacterial protein synthesis.
   Side effects: GI upset; rare QT issues.

6. Inhaled bronchodilator (e.g., albuterol/salbutamol)
   Class: short-acting beta-agonist.
   Dose/Time: as-needed for wheeze.
   Purpose: relieve reactive airway symptoms during infections.
   Mechanism: airway smooth muscle relaxation.
   Side effects: tremor, palpitations.

7. Intranasal corticosteroid (e.g., fluticasone)
   Class: topical steroid.
   Dose/Time: once or twice daily for rhinitis.
   Purpose: reduce nasal inflammation and eustachian tube dysfunction.
   Mechanism: anti-inflammatory gene regulation.
   Side effects: local irritation, epistaxis.

8. Montelukast
   Class: leukotriene receptor antagonist.
   Dose/Time: once daily.
   Purpose: adjunct for upper airway/allergy-related symptoms.
   Mechanism: blocks leukotriene D4 receptor.
   Side effects: rare mood changes.

9. Antihistamine (e.g., cetirizine)
   Class: H1 blocker.
   Dose/Time: daily or pre-ERT.
   Purpose: allergy control; infusion pre-medication.
   Mechanism: blocks histamine receptor.
   Side effects: drowsiness (less with second-generation).

10. Corticosteroid (short course; e.g., prednisone)
    Class: systemic steroid.
    Dose/Time: short tapers for significant airway inflammation, or as pre-medication for prior infusion reactions when advised.
    Purpose: reduce inflammation or prevent severe infusion reactions.
    Mechanism: broad anti-inflammatory effects.
    Side effects: mood change, hyperglycemia, infection risk; avoid long-term use unless necessary. FDA Access Data

11. Antibiotic ear drops (e.g., ofloxacin) after tube placement
    Class: topical antibiotic.
    Dose/Time: short course if otorrhea.
    Purpose: treat ear discharge/infection.
    Mechanism: local bacterial killing.
    Side effects: local irritation.

12. Antiepileptic (e.g., levetiracetam) if seizures present
    Class: anticonvulsant.
    Dose/Time: titrated by neurology.
    Purpose: control seizures reported in some patients.
    Mechanism: synaptic modulation (SV2A).
    Side effects: mood irritability, somnolence.

13. Prophylactic antibiotics in very frequent bacterial exacerbations (selected cases)
    Class: various (ENT/pulmonary guidance).
    Dose/Time: low-dose nightly or cyclic, specialist-guided.
    Purpose: reduce infection frequency.
    Mechanism: suppress recurrent bacterial growth.
    Side effects: resistance, GI upset—specialist oversight essential.

14. Vitamin D (cholecalciferol)
    Class: vitamin.
    Dose/Time: per deficiency or maintenance per labs.
    Purpose: bone health in low mobility or steroid exposure.
    Mechanism: improves calcium absorption.
    Side effects: very high doses may cause hypercalcemia.

15. Calcium (elemental) if dietary intake low
    Class: mineral supplement.
    Dose/Time: divided doses with meals.
    Purpose: bone health support.
    Mechanism: mineral for bone matrix.
    Side effects: constipation; kidney stones if excessive.

16. IV immunoglobulin (IVIG) in selected patients with significant antibody deficiency and recurrent severe infections
    Class: pooled IgG.
    Dose/Time: typically every 3–4 weeks per immunology.
    Purpose: reduce serious infections in immune-deficient patients.
    Mechanism: provides functional antibodies.
    Side effects: infusion reactions, headache; rare thrombosis—specialist decision.

17. Nebulized hypertonic saline (airway clearance adjunct)
    Class: osmotic airway therapy.
    Dose/Time: 3–7% saline via nebulizer per respiratory team.
    Purpose: thin mucus to aid clearance.
    Mechanism: draws water into airway secretions.
    Side effects: cough/bronchospasm (premedicate with bronchodilator if needed).

18. Proton-pump inhibitor (e.g., omeprazole) if reflux worsens airway issues
    Class: acid suppressant.
    Dose/Time: once daily trial if GERD symptoms.
    Purpose: reduce reflux-related cough/aspiration risk.
    Mechanism: blocks gastric acid pump.
    Side effects: headache; long-term risks—use only if indicated.

19. Analgesic adjuvants (e.g., topical diclofenac gel)
    Class: topical NSAID.
    Dose/Time: applied to painful joints as labeled.
    Purpose: local pain relief with less systemic exposure.
    Mechanism: local COX inhibition.
    Side effects: skin irritation; avoid broken skin.

20. Peri-HSCT medications (specialist-directed)
    Class: conditioning/anti-infective/anti-rejection (e.g., busulfan, fludarabine, tacrolimus; antimicrobials per protocol).
    Dose/Time: transplant protocols only.
    Purpose: enable engraftment and prevent complications.
    Mechanism: reduce host marrow; modulate immunity; prevent infections.
    Side effects: significant—transplant center oversight only. ASTCT Journal

---

Dietary molecular supplements

1. Vitamin D3—typical daily dosing per labs; supports bone and muscle function by improving calcium use.

2. Calcium—meets daily needs if diet is low; builds bone matrix; avoid excess.

3. Omega-3 fatty acids (fish oil)—1–2 g/day EPA+DHA; may help joint stiffness and general inflammation by resolving lipid mediators.

4. Vitamin C—100–200 mg/day from food/supplement; supports immune function and collagen formation.

5. Zinc—up to 10–20 mg/day short-term if deficient; cofactor in immune activity; avoid long-term excess (copper deficiency).

6. Protein supplementation (whey, casein, or plant protein)—helps maintain muscle mass in low mobility by supplying amino acids.

7. Probiotics (specific strains)—may reduce antibiotic-associated diarrhea and support gut barrier; mechanism via microbiota effects.

8. Magnesium (diet or supplement)—supports muscle and nerve function; helpful if cramps occur.

9. Folate and B12 (if low on labs)—support red blood cells and nerve function; correct documented deficiency.

10. Fiber (psyllium/food)—supports bowel regularity and gut health, especially with low activity.

(These do not treat storage material; they support overall health alongside ERT/HSCT.)

---

Immunity-booster / regenerative / stem-cell

There are no approved “stem-cell pills” for alpha-mannosidosis. “Regeneration” in this disease is addressed through HSCT (a procedure) and ERT. The items below are medications used around those therapies or for immune support in specific situations, always under a specialist.

1. Velmanase alfa (ERT) – replacement enzyme; indirectly improves infection burden by correcting systemic enzyme deficiency outside the brain. FDA Access Data+1

2. IVIG – antibody replacement in selected patients with proven antibody deficiency and severe, recurrent infections.

3. G-CSF (filgrastim) – stimulates neutrophils if severe neutropenia occurs (e.g., during HSCT phases); short courses only.

4. Vaccines (inactivated) per schedule – not a “drug” in the classic sense but the most effective evidence-based immune tool; timing may be adjusted around HSCT/ERT.

5. Antimicrobial prophylaxis during HSCT – targeted antivirals/antibacterials/antifungals to protect while immunity is low (protocol-driven). ASTCT Journal

6. Conditioning/anti-rejection agents (e.g., busulfan, fludarabine, tacrolimus) – enable donor stem cells to engraft; these are not disease cures alone, but part of HSCT aimed at long-term enzyme supply. ASTCT Journal

---

Surgeries

1. Tympanostomy (ventilation) tube insertion
   Why: recurrent middle-ear infections or fluid causing hearing loss. Helps equalize pressure and reduce infections; often paired with hearing management. BioMed Central

2. Adenoidectomy/tonsillectomy
   Why: obstructive sleep apnea or frequent infections; improves airway and sleep quality in selected patients. BioMed Central

3. Orthopedic surgery (e.g., spinal fusion for scoliosis, tendon releases, foot reconstruction)
   Why: prevent progression of deformity, improve function, reduce pain when bracing/therapy are not enough. BioMed Central

4. Ophthalmic surgery (cataract extraction or strabismus correction)
   Why: improve vision and eye alignment when glasses/patching are insufficient. BioMed Central

5. Ventriculoperitoneal shunt (if hydrocephalus occurs)
   Why: drain extra cerebrospinal fluid to lower pressure and protect brain function; considered in selected cases reported in the condition. BioMed Central

---

Preventions

1. Keep vaccinations up to date; seek advice on extra timing around HSCT/ERT. BioMed Central

2. Prompt ENT and dental care to limit infection sources. BioMed Central

3. Hand hygiene and avoid sick contacts during peak seasons.

4. Early hearing checks to prevent speech delay. BioMed Central

5. Regular physiotherapy to maintain mobility and prevent contractures.

6. Healthy weight and nutrition to support bones and immunity.

7. Sleep apnea screening if snoring, pauses, or daytime sleepiness.

8. Protect the spine and hips with posture guidance and proper seating.

9. Allergy control to reduce ENT swelling and secondary infections.

10. Care coordination so treatments aren’t missed and side effects are caught early. Genetic and Rare Diseases Center

---

When to see a doctor (red flags)

• More frequent or severe ear, sinus, chest, or skin infections.

• New or worsening hearing loss, speech regression, or school decline.

• New headaches, vomiting, vision changes, or seizures.

• Breathing pauses at night, loud snoring, or daytime sleepiness.

• Rapid changes in walking, balance, or joint pain/swelling.

• Infusion reactions during ERT: fever, chills, rash, wheeze, swelling, or fainting—seek urgent care. FDA Access Data

---

What to eat and what to avoid

What to eat:

• A balanced plate: whole grains, fruits, vegetables, lean proteins, and healthy fats.

• Protein at each meal to maintain muscles if activity is limited.

• Calcium- and vitamin-D-rich foods (dairy or fortified alternatives; fish with bones; leafy greens).

• Fluids to keep mucus loose when sick.

• High-fiber options for regular bowels, especially if less active.

What to avoid or limit:

• Excess ultra-processed foods high in sugar/salt—can worsen weight and energy levels.

• Large, late heavy meals if reflux worsens cough or sleep.

• Herbal “enzyme” or “stem cell” products claiming cures—no evidence and possible harm; always discuss supplements with your clinician.

---

Frequently asked questions (FAQs)

1. Is alpha-mannosidosis contagious?
   No. It is a genetic condition present from birth.

2. Can it be cured?
   There is no simple cure. ERT treats many body symptoms outside the brain. HSCT may help broader disease (including neurodevelopment) if done early but has risks. Supportive care remains key. U.S. Food and Drug Administration+1

3. Will ERT help learning problems?
   ERT mainly helps non-CNS symptoms; it does not cross the blood–brain barrier well, so brain-related issues may change less. U.S. Food and Drug Administration

4. How is Lamzede® given and how often?
   By IV infusion once a week at 1 mg/kg. Infusion centers or trained home services may be used per local practice. FDA Access Data+1

5. What are common side effects of Lamzede®?
   Infusion reactions (fever, chills, rash), headache, joint pain; rare serious allergy. Teams often pre-medicate to prevent reactions. FDA Access Data

6. If my child is doing ERT, do we still need therapy and hearing support?
   Yes. ERT is one part of care; therapy, hearing devices, ENT, dental, and school supports remain important. BioMed Central

7. Who should be considered for HSCT?
   Typically, selected young children with severe disease before major decline. A transplant center weighs risks and benefits for each case. ScienceDirect

8. Can adults start ERT?
   Yes—Lamzede® is approved for pediatric and adult patients for non-CNS symptoms. FDA Access Data

9. Will ERT stop infections?
   It may reduce the burden of infections by improving immune function markers and systemic health but will not remove all risk; vaccinations and ENT/dental care still matter. ScienceDirect

10. Is gene therapy available?
    No approved gene therapy yet; research is ongoing in lysosomal diseases generally.

11. Can diet cure this disease?
    No. Diet supports overall health and bones but does not remove stored sugars.

12. Is pregnancy possible?
    Many people can have children. Genetic counseling helps discuss carrier testing and options.

13. Should siblings be tested?
    Yes, if a pathogenic MAN2B1 variant is known in the family; early diagnosis guides care. NCBI

14. What specialists should be on our team?
    Metabolic/genetic specialists, pediatrics/neurology, ENT/audiology, orthopedics/physiatry, ophthalmology, dentistry, nutrition, psychology, social work. Genetic and Rare Diseases Center

15. Where can I find reliable information?
    GeneReviews®, Orphanet, NORD, GARD, and the FDA label for Lamzede®. FDA Access Data+4NCBI+4Orpha+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 13, 2025.

PDF Documents For This Disease Condition References